TY - JOUR T1 - Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA655 VL - 58 IS - suppl 65 SP - PA655 AU - Sivagurunathan Sutharsan AU - Marc Berger AU - Jitka Andrä AU - Lutz-Bernhard Jehn AU - Christian Taube AU - Thorsten Brenner AU - Simone Kattner AU - Andreas Limmer AU - Francesco Bonella Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA655.abstract N2 - Introduction: SARS-CoV2 infection is associated with an extremely variable disease course. Direct damage of type II pneumocytes is suspected to play a role in mediating and perpetuating lung damage. Serum KL-6, a lung epithelial mucin, is an established marker of interstitial pneumonia (IP).Objectives: To investigate a possible role of serum KL-6 levels as a biomarker to predict outcome in patients with SARS-CoV2 infection.Methods: Consecutive patients admitted at Emergency Department with SARS-CoV2 infection were included and followed. Infection was confirmed by RT-PCR test. The WHO Ordinal Scale for Clinical Improvement (0-8 points) was used to classify the clinical course. Serum samples were collected at admission and KL-6 was measured by using automated CLIA immunoassay (Fujirebio). Upper limit of normal was set at 486 U/mL based on previous measurement in our laboratory.Results: 158 patients (97 M, 61 F, age 61±16 years) were included. 38 patients (87%) developed pneumonia, 63 (40%) requiring NIV, IV or ECMO. 15 (9%) of them died during hospitalisation. Mean Serum KL-6 level at admission was 566±45 U/mL (range:125-5822 U/mL). Patients requiring NIV, IV or ECMO had significantly higher serum KL-6 levels at admission compared to those with mild disease (748±81 vs 386±25, respectively, p<0.0001). A significant correlation between serum KL-6 levels and WHO-outcome scale score was observed (r=0.541, p=0.0002). Serum KL-6 levels were tendentially higher in patients who died than in those who survived (710±142 vs 553±47, respectively).Conclusions: Serum KL-6 seems to be a useful biomarker to stratify patients with SARS-CoV2 infection for risk of worse disease outcome at admission.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA655.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -